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Over the past year, results of several randomized clinical
trials (eg, Substrate and Trigger Ablation for Reduction of
Atrial Fibrillation Trial Part II (STAR AF 2), No Beneﬁt OF
Complex Fractionated Atrial Electrogram (CFAE) Ablation
in Addition to Circumferential Pulmonary Vein Ablation and
Linear Ablation (BOCA) and Catheter Ablation of Persistent
Atrial Fibrillation Study (CHASE AF)) have shown no
beneﬁt of adding either CFAE or linear ablation to pulmo-
nary vein isolation (PVI) compared with PVI in patients with
persistent atrial ﬁbrillation (AF).1–3 These results raise an
important question: Is CFAE a wrong target for AF ablation?
Over the past 15 years, our centers have been performing
CFAE ablation without PVI in patients with AF, with great
success in maintaining sinus rhythm (SR) and improving key
clinical outcomes such as stroke and mortality reduction.4–6
Therefore, we are conﬁdent that ablation targeting CFAE
sites is indeed effective. The objectives of this article are to
(1) explain why CFAE ablation is still relevant; (2) describe
how we select appropriate CFAE sites that represent AF
substrates; and (3) discuss the controversies of CFAE
ablation and the differences between our ablative approach
and others that combine CFAE and PVI.Are CFAE sites AF substrate sites?
Any increased variability in the velocity or directionality of the
atrial electrical impulse may set the stage for electrogram (EGM)
fractionation. Therefore, any heterogeneities—anatomic, func-
tional, macroscopic, or microscopic— can underlie CFAEs.7KEYWORDS Ablation; Atrial ﬁbrillation; Mapping; Atrial ﬂutter (Heart
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10.1016/j.hrthm.2016.06.036Practically, impulse direction and velocity changes are most
likely to be associated with delays, intermittent block, wave
breaks, and rotors. For example, it was reported that CFAEs are
commonly found in areas of slow conduction or pivot points
where the wavefront turns around the end of the arch of the
functional block.8 Another example is the stimulation of para-
sympathetic ﬁbers within the ganglionic plexi, which has been
shown to colocalize with CFAEs in both animal and humanAF.9
In recent years, there has been a growing interest in the
role of rotors as the main mechanism of AF and its
association with CFAEs. Kalifa et al10 demonstrated that
CFAEs are predominantly found at the boundaries of the
highest frequency of excitation (mother rotors). Also, it was
suggested that a high degree of irregularity and fractionation is
present at the rotor tip.11 Finally, a higher degree of EGM
fractionation was predicted by numerical simulations mimick-
ing the propagation of the rotor’s wavefront in ﬁbrotic tissues.12
Narayan et al13 have published studies in humans using
impulse and rotor modulation to guide ablation with good
results, generating excitement and interest in using rotor
mapping to guide AF ablation. However, they found that
rotors serving as the drivers perpetuating AF correlate poorly
with CFAE. In contrast, Haissaguerre et al14 recently reported
their observation of the relationship between reentrant drivers
and focal drivers with CFAE. They found that prolonged
fractionated EGMs were more frequently recorded at the
reentrant driver (repetitive rotor) regions (62% vs 40%; odds
ratio 3.41; 95% conﬁdence interval 1.07–10.95; P ¼ .04).
The difference in results between these 2 studies remains
unclear. We speculate that their different methods of identi-
fying rotors and different deﬁnitions of CFAE may underlie
these discrepancies (Online Supplemental Table 1).Which CFAE to be ablated?
Interestingly, the characteristics described by Haissaguerre
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described.4 This underscores our viewpoint that the most
important ﬁrst step for a successful CFAE ablation procedure
is to choose which CFAE sites are to be ablated and to
recognize that not all CFAEs are the same.
We choose ablation sites that harbor CFAEs characterized
by the following EGMs: (1) low-voltage (range 0.04–0.25
mV) signals that have multiple potentials with continuous
deﬂection of a prolonged activation complex (Online
Supplement Figure 1A); (2) stationary CFAEs that have
temporal and spatial stability; and (3) short–cycle length
(CCL 50–120 ms) EGMs that occur repeatedly with a
relatively stable frequency with or without multiple poten-
tials as CFAEs (Online Supplement Figure 1B). These types
of short-CCL EGMs are usually located around the antrum of
the pulmonary vein (PV). Their CCL, the so-called AF
drivers or rapid ﬁre EGMs (o80% of the mean AF CCL),
are often the shortest as compared to the rest of the atria. We
do not recommend ablating CFAE sites that are ﬂeeting,
have high amplitude, or have a relatively long CCL (4150
ms) (Online Supplemental Figures 1C and 2).
The proof that CFAE sites represent substrate sites is
based on our ﬁndings that by ablating CFAEs, we have
successfully terminated AF to SR in 480% of our patients
(Online Supplemental Appendix 1) and yield good long-term
outcomes even in high-risk subsets (Online Supplemental
Appendix 1).4,9,15 The typical response of CFAE ablation
procedures for persistent AF is a progressive increase in
CCL, and AF becomes more organized and changes to atrial
tachycardia (AT) or atrial ﬂutter (AFL), which is mapped and
ablated until the rhythm is converted to SR. It is rare for
persistent AF to be reverted to SR without changing to AT/
AFL ﬁrst. The mechanisms underlying the transformation of
AF to AT/AFL may be multifactorial: (1) Fibrillatory
conduction of either driving rotors or focal source have been
altered or eliminated by CFAE ablation so that the ﬁbrillation
wavelets could no longer reenter the ablated areas. (2)
Termination of the wavelet at the dead ends or circling of
the wavelets around the ablated areas result in a more
organized rhythm of a new macroreentrant circuit with a
longer CCL. The random reentry changes to a single
macroreentrant circuit, a focal reentry, or a focal discharge.
(3) Some of these ATs/AFLs were the primary arrhythmias
that induced AF via ﬁbrillatory conduction that became
manifested after CFAE ablation.
The ultimate task is to identify arrhythmogenic site(s)
perpetuating this AT/AFL. We search for the residual CFAE
around the tagged and/or previously ablated areas, occasion-
ally with ibutilide: The drug is invaluable in guiding us to
identify either the reentrant circuits or the focal source of the
tachycardia. The 2 key effects of ibutilide are as follows: (1)
The drug lengthens the CCL of tachycardia globally but less
so at the arrhythmogenic site, which then creates a clear
pattern of frequency gradient between the arrhythmogenic
site(s) and the rest of the atria (Online Supplemental
Figure 2). (2) Ibutilide markedly lengthens the tachycardia
CCL and brings forth an identiﬁable P wave, enabling anoperator to map the circuit much easily. (3) Elimination of
a residual ﬁbrillatory conduction unmasks the primary
arrhythmia. We also search for the earliest activation or
mid-diastolic potential for the tachycardia that has stable
CCL and activation pattern.
Long-term outcomes with CFAE ablation
procedures in high-risk populations
We have reported our excellent results of CFAE ablation in
high-risk patients similar to those in the AFFIRM study,5 not
only in maintaining SR but also in mortality and stroke
reduction. We further expanded this observation in the
elderly population (older than 75 years), which included
189 patients with persistent AF (129 had long-standing
persistent AF)6; 63 of those 189 (33%) patients had
implantable devices that allowed us to accurately assess
AF burden. We were able to terminate AF to SR in 156 of
189 patients (82%). Our mean times for procedure (138 ± 41
minutes), ﬂuoroscopy (8 ± 3.6 minutes), and cumulative
radiofrequency (40 ± 21 minutes) were quite shorter than
those reported in the STAR AF II and BOCA trials. After a
mean follow-up of 4 years, freedom from AF was achieved
in 78% and was strongly supported by the data of AF burden
in these patients. Warfarin therapy was discontinued in 80%
of the patients who maintained SR, and they had low (3%) 5-
year stroke/bleeding rates.
Our results are by far much better than PVI alone or
hybrid PVI ablation. Therefore, we ﬁrmly believe that we
should not change our ablation approach until an approach
that produces a better result than ours is established.
Why the results of recent trials show no
incremental beneﬁts of CFAE plus PVI ablation
Why do the outcomes of these studies not improve when
adding CFAE ablation after PVI as compared with PVI? The
answer to this question could be that either CFAE areas are
not true substrate sites or the methodology or conducts of
these studies are ﬂawed. It may be difﬁcult to question the
results of these randomized clinical trials, which all show
ineffectiveness of hybrid PVI ablation with adjuvant CFAE
ablation procedures. However, one has to recognize that
randomized trials are designed only to minimize confound-
ing variables of study patients between the treatment and
control groups and to ensure that both groups have the same
distribution of patients with respect to the underlying disease
and its severity. These trials also assume that there are no
confounding variables associated with how treatment is
delivered and how end points are measured. This assumption
is correct when one compares a straightforward intervention
such as a new medication or a noncomplicated procedure vs
a placebo or no treatment. However, this assumption cannot
be applied for AF ablation procedures of persistent AF,
especially when one adds CFAE ablation procedures into the
mix. Randomization cannot control the comprehensiveness
of CFAE mapping done at each center, nor can it account for
the operator skill and proﬁciency in CFAE ablation, or the
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fact that there are low rates of AF termination to SR in these
randomized studies suggests that there are differences in the
CFAE ablation techniques they used compared to ours.
First, by performing PVI before CFAE ablation, if one
just merely draws circles around the 4 PVs as shown in the
STAR AF II diagram, the circles around the PVs are made by
deﬁnition 2 cm away from the actual ostium of the PV
(Online Supplemental Figure 3), it results in wide circles
around the PV antra. One may completely ignore CFAE sites
inside the circles around the PVs, which will result in
incomplete CFAE ablation procedures.
Both STAR AF II and CHASE-AF investigators relied on
the software detection of CFAE sites for guiding ablation.
Although the software for CFAE detection (EnSite, St Jude
Medical, St Paul, MN and CARTO, BiosenseWebster,
Diamond Bar, CA) is supposed to help operators identify
CFAE target sites, it is ﬂawed because of its inability to
accurately detect the primary CFAE sites with low voltage
and short CCL.
In our laboratories, we depend more on our own visual-
ization and manual correction of CFAE sites; therefore, we
do not rely on the color display of CFAE sites by the
software to ablate good CFAE sites. Albeit, this results in
signiﬁcant degrees of subjectivity as we ablate over much
smaller areas than if we relied solely on the software
detection of CFAE. This can be seen when we compare
the typical locations of CFAE sites from our centers with
those of STAR AF II (Online Supplemental Figure 3). The
common CFAE sites of STAR AF II are located in the
posterior wall close to the roof and in the middle of the
posterior wall; these are not the usual sites we ablate. Our
common sites are typically at the antra of PVs, septal wall,
posterior mitral annulus, mouth or atrial appendage, and
coronary sinus.
On the basis of these ﬁndings, we believe that the CFAE
sites ablated by the operators in these studies are likely to be
different from ours; and thus, it is not surprising that CFAE
ablation procedures in these studies are ineffective.Future of CFAE ablation and concluding remarks
We are conﬁdent that good CFAE sites represent substrate
sites, and when one ablates such sites, one is likely to
terminate AF without having to routinely performing PVI.
Those still wanting to continue to combine trigger and
substrate ablation procedures by targeting CFAE should
perform CFAE ablation before PVI since the PV antra
commonly harbor target CFAE.
The major limitations of CFAE ablation are (1) the
subjectivity in selecting CFAE sites and thus the need for
further reﬁnement and development of CFAE mapping tools
to help identify CFAE target sites with more objectivity and
reproducibility, and (2) the lack of randomized trials involv-
ing operators who perform the technique regularly in their
laboratories to compare this technique with other ablative
approaches or with other treatments, that is, antiarrhythmicdrugs with respect to SR maintenance and/or composite end
points (death, cardiovascular events, and stroke).
To this end, we are conducting an international
multicenter trial, CIPA (clinicaltrials.gov Identiﬁer
NCT02696265), which stands for the clinical randomized
trial of CFAE-guided ablation vs PVI-guided ablation in
persistent AF. The goal of CIPA is to compare the efﬁcacy
and safety of CFAE-guided ablation with those of PVI-based
ablation in patients with persistent AF. We believe that once
we have a large amount of randomized multicenter data to
conﬁrm a single-site study, thus improving how we select
CFAE sites for ablation, our approach will then be an integral
part of AF ablation in the future.
Appendix
Supplementary data
Supplementary data are available in the online version of this
article at http://dx.doi.org/10.1016/j.hrthm.2016.06.036.References
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